Chemomab Therapeutics Ltd DRC

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing therapeutics for fibrotic and inflammatory diseases. Its lead product candidate, nebokitug, is a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways. Nebokitug has completed a phase 2 clinical trial for primary sclerosing cholangitis and is in a phase 2 clinical trial for systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.